Differential Impact of Neurofilament Light Subunit on Cognition and Functional Outcome in Memory Clinic Patients with and without Vascular Burden

Journal of Alzheimer's Disease

Volumn 45, Issue 3, 2015, Pages 873-881

  Rolstad, Sindre ^a   Berg, Anne Ingeborg ^b   Eckerström, Carl ^a   Johansson, Boo ^b   Wallin, Anders ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Amyloid 1 42; cerebrospinal fluid; cognition; dementia; mild cognitive impairment; neurofilament light subunit; subjective cognitive impairment

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; NEUROFILAMENT LIGHT SUBUNIT; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); NEUROFILAMENT PROTEIN; NEUROFILAMENT PROTEIN L; PEPTIDE FRAGMENT;

ADULT; AGED; ARTICLE; BRAIN FUNCTION; CEREBROSPINAL FLUID; CEREBROVASCULAR DISEASE; CLINICAL DEMENTIA RATING; COGNITION; DEMENTIA; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GLOBAL DETERIORATION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; MYELINATED NERVE; NERVE FIBER; NEUROFILAMENT; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RATING SCALE; SEMI STRUCTURED INTERVIEW; WHITE MATTER LESION; COGNITIVE DEFECT; COMPLICATION; MEMORY DISORDERS; METABOLISM; MIDDLE AGED; NEUROIMAGING; VASCULAR DISEASE;

AGED; AMYLOID BETA-PEPTIDES; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MEMORY DISORDERS; MIDDLE AGED; NEUROFILAMENT PROTEINS; NEUROIMAGING; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; VASCULAR DISEASES;

EID: 84925781019     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-142694     Document Type: Article

References (59)

1. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC (2004) Mild cognitive impairment-beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256, 240-246.
2. Blennow K (2004) CSF biomarkers for mild cognitive impairment. J Intern Med 256, 224-234.
3. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59, 512-519.
4. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttila T, Wallin A, Jonhagen ME, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302, 385-393.
5. Aggarwal NT, Decarli C (2007) Vascular dementia: Emerging trends. Semin Neurol 27, 66-77.
6. Skoog I, Davidsson P, Aevarsson O, Vanderstichele H, Vanmechelen E, Blennow K (2003) Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: A population-based study in 85-year-olds. Dement Geriatr Cogn Disord 15, 169-176.
7. Schoonenboom N, Reesink F, Verwey N, Kester M, Teunissen C, van de Ven P, Pijnenburg Y, Blankenstein M, Rozemuller A, Scheltens P, van der Flier W (2012) Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 78, 47-54.
8. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K (2001) Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58, 373-379.
9. Chui HC (2006) Vascular cognitive impairment: Today and tomorrow. Alzheimers Dement 2, 185-194.
10. Schlaepfer WW, Lynch RG (1977) Immunofluorescence studies of neurofilaments in the rat and human peripheral and central nervous system. J Cell Biol 74, 241-250.
11. Petzold A (2005) Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 233, 183-198.
12. Hjalmarsson C, Bjerke M, Andersson B, Blennow K, Zetterberg H, Aberg ND, Olsson B, Eckerstrom C, Bokemark L, Wallin A (2014) Neuronal and glia-related biomarkers in cerebrospinal fluid of patients with acute ischemic stroke. J Cent Nerv Syst Dis 6, 51-58.
13. Rosengren LE, Karlsson JE, Sjogren M, Blennow K, Wallin A (1999) Neurofilament protein levels in CSF are increased in dementia. Neurology 52, 1090-1093.
14. Sjogren M, Blomberg M, Jonsson M, Wahlund LO, Edman A, Lind K, Rosengren L, Blennow K, Wallin A (2001) Neurofilament protein in cerebrospinal fluid: A marker of white matter changes. J Neurosci Res 66, 510-516.
15. Jonsson M, Zetterberg H, van Straaten E, Lind K, Syversen S, Edman A, Blennow K, Rosengren L, Pantoni L, Inzitari D, Wallin A (2010) Cerebrospinal fluid biomarkers of white matter lesions - cross-sectional results from the LADIS study. Eur J Neurol 17, 377-382.
16. Zanier ER, Refai D, Zipfel GJ, Zoerle T, Longhi L, Esparza TJ, Spinner ML, Bateman RJ, Brody DL, Stocchetti N (2011) Neurofilament light chain levels in ventricular cerebrospinal fluid after acute aneurysmal subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 82, 157-159.
17. Lycke JN, Karlsson JE, Andersen O, Rosengren LE (1998) Neurofilament protein in cerebrospinal fluid: A potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 64, 402-404.
18. Bjerke M, Andreasson U, Rolstad S, Nordlund A, Lind K, Zetterberg H, Edman A, Blennow K, Wallin A (2009) Subcortical vascular dementia biomarker pattern in mild cognitive impairment. Dement Geriatr Cogn Disord 28, 348-356.
19. Wallin A, Sjogren M (2001) Cerebrospinal fluid cytoskeleton proteins in patients with subcortical white-matter dementia. Mech Ageing Dev 122, 1937-1949.
20. Petzold A, Keir G, Warren J, Fox N, Rossor MN (2007) A systematic review and meta-analysis of CSF neurofilament protein levels as biomarkers in dementia. Neurodegener Dis 4, 185-194.
21. Rolstad S, Berg AI, Bjerke M, Blennow K, Johansson B, Zetterberg H, Wallin A (2011) Amyloid-beta(4)(2) is associated with cognitive impairment in healthy elderly and subjective cognitive impairment. J Alzheimers Dis 26, 135-142.
22. Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O (2010) CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology 74, 1531-1537.
23. Schoonenboom SN, Visser PJ, Mulder C, Lindeboom J, Van Elk EJ, Van Kamp GJ, Scheltens PH (2005) Biomarker profiles and their relation to clinical variables in mild cognitive impairment. Neurocase 11, 8-13.
24. Rolstad S, Berg AI, Bjerke M, Johansson B, Zetterberg H, Wallin A (2013) Cerebrospinal fluid biomarkers mirror rate of cognitive decline. J Alzheimers Dis 34, 949-956.
25. Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, Xiong C, Morris JC, Holtzman DM (2009) Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol 66, 638-645.
26. Nordlund A, Rolstad S, Hellstrom P, Sjogren M, Hansen S, Wallin A (2005) The Goteborg MCI study: Mild cognitive impairment is a heterogeneous condition. J Neurol Neurosurg Psychiatry 76, 1485-1490.
27. Nordlund A, Rolstad S, Klang O, Lind K, Hansen S, Wallin A (2007) Cognitive profiles of mild cognitive impairment with and without vascular disease. Neuropsychology 21, 706-712.
28. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
29. Reisberg B, Ferris SH, de Leon MJ, Crook T (1988) Global Deterioration Scale (GDS). Psychopharmacol Bull 24, 661-663.
30. Wallin A, Edman A, Blennow K, Gottfries CG, Karlsson I, Regland B, Sjogren M (1996) Stepwise comparative status analysis (STEP): A tool for identification of regional brain syndromes in dementia. J Geriatr Psychiatry Neurol 9, 185-199.
31. Royall DR, Mahurin RK, Gray KF (1992) Bedside assessment of executive cognitive impairment: The executive interview. J Am Geriatr Soc 40, 1221-1226.
32. Morris JC (1997) Clinical dementia rating: A reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr 9 Suppl 1, 173-176; discussion 177-178.
33. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
34. Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, Roman GC, Chui H, Desmond DW (2000) Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl 59, 23-30.
35. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A et al. (1993) Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43, 250-260.
36. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 65, 1863-1872.
37. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF (1998) Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology 51, 1546-1554.
38. (1994) Diagnostic and statistical manual of mental disorders, American Psychiatric Publishing, Inc., Arlington, VA.
39. Scheltens P, Erkinjunti T, Leys D, Wahlund LO, Inzitari D, del Ser T, Pasquier F, Barkhof F, Mantyla R, Bowler J, Wallin A, Ghika J, Fazekas F, Pantoni L (1998) White matter changes on CT and MRI: An overview of visual rating scales. European Task Force on Age-Related White Matter Changes. Eur Neurol 39, 80-89.
40. (1996) Assessment: Neuropsychological testing of adults. Considerations for neurologists. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 47, 592-599.
41. Lezak M, Howieson D, Bigler E, Tranel D (2012) Neuropsychological Assessment, Oxford University Press.
42. Strauss E, Sherman EMS, Spreen O (2006) A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary, Oxford University Press.
43. Zetterberg H, Pedersen M, Lind K, Svensson M, Rolstad S, Eckerstrom C, Syversen S, Mattsson UB, Ysander C, Mattsson N, Nordlund A, Vanderstichele H, Vanmechelen E, Jonsson M, Edman A, Blennow K, Wallin A (2007) Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. J Alzheimers Dis 12, 255-260.
44. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K (1999) Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: Differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 56, 673-680.
45. Rosengren L, Karlsson J, Karlsson J, Persson L, Wikkelsø C (1996) Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 67, 2013-2018.
46. Cohen J (1988) Statistical power analysis for the behavioural sciences, Erlbaum, NJ.
47. Skillback T, Zetterberg H, Blennow K, Mattsson N (2013) Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples. Alzheimers Res Ther 5, 47.
48. Debette S, Beiser A, DeCarli C, Au R, Himali JJ, Kelly-Hayes M, Romero JR, Kase CS, Wolf PA, Seshadri S (2010) Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: The Framingham Offspring Study. Stroke 41, 600-606.
49. Jokinen H, Kalska H, Ylikoski R, Madureira S, Verdelho A, Gouw A, Scheltens P, Barkhof F, Visser MC, Fazekas F, Schmidt R, O'Brien J, Hennerici M, Baezner H, Waldemar G, Wallin A, Chabriat H, Pantoni L, Inzitari D, Erkinjuntti T, group L (2009) MRI-defined subcortical ischemic vascular disease: Baseline clinical and neuropsychological findings. The LADIS Study. Cerebrovasc Dis 27, 336-344.
50. Jokinen H, Kalska H, Mantyla R, Pohjasvaara T, Ylikoski R, Hietanen M, Salonen O, Kaste M, Erkinjuntti T (2006) Cognitive profile of subcortical ischaemic vascular disease. J Neurol Neurosurg Psychiatry 77, 28-33.
51. Prins ND, van Dijk EJ, den Heijer T, Vermeer SE, Jolles J, Koudstaal PJ, Hofman A, Breteler MM (2005) Cerebral small-vessel disease and decline in information processing speed, executive function and memory. Brain 128, 2034-2041.
52. Sachdev PS, Brodaty H, Valenzuela MJ, Lorentz L, Looi JC, Wen W, Zagami AS (2004) The neuropsychological profile of vascular cognitive impairment in stroke and TIA patients. Neurology 62, 912-919.
53. Zanetti M, Ballabio C, Abbate C, Cutaia C, Vergani C, Bergamaschini L (2006) Mild cognitive impairment subtypes and vascular dementia in community-dwelling elderly people: A 3-year follow-up study. J Am Geriatr Soc 54, 580-586.
54. Graham NL, Emery T, Hodges JR (2004) Distinctive cognitive profiles in Alzheimer's disease and subcortical vascular dementia. J Neurol Neurosurg Psychiatry 75, 61-71.
55. Inzitari D, Simoni M, Pracucci G, Poggesi A, Basile AM, Chabriat H, Erkinjuntti T, Fazekas F, Ferro JM, Hennerici M, Langhorne P, O'Brien J, Barkhof F, Visser MC, Wahlund LO, Waldemar G, Wallin A, Pantoni L, Group LS (2007) Risk of rapid global functional decline in elderly patients with severe cerebral age-related white matter changes: The LADIS study. Arch Intern Med 167, 81-88.
56. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR Jr, Alzheimer's Disease Neuroimaging Initiative (2009) MRI and CSF biomarkers in normal, MCI, and AD subjects: Predicting future clinical change. Neurology 73, 294-301.
57. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128.
58. Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, Berg L (2001) Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 58, 397-405.
59. Nordlund A, Rolstad S, Klang O, Edman A, Hansen S, Wallin A (2009) Two year outcome of MCI subtypes and aetiologies in the Goteborg MCI study. J Neurol Neurosurg Psychiatry 81, 541-546.